These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37739241)

  • 21. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
    Mezzatesta ML; La Rosa G; Maugeri G; Zingali T; Caio C; Novelli A; Stefani S
    Int J Antimicrob Agents; 2017 Jun; 49(6):763-766. PubMed ID: 28390962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
    García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
    J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K; Grey J; Fronczek C; Marr K
    Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Community-Acquired Uropathogenic
    Carmona-Cartaya Y; Hidalgo-Benito M; Borges-Mateus LM; Pereda-Novales N; González-Molina MK; Quiñones-Pérez D
    MEDICC Rev; 2022 May; 24(2):20-25. PubMed ID: 35648059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
    de Cueto M; Hernández JR; López-Cerero L; Morillo C; Pascual A
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):613-6. PubMed ID: 17194386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines.
    Muvunyi CM; Masaisa F; Bayingana C; Mutesa L; Musemakweri A; Muhirwa G; Claeys GW
    Am J Trop Med Hyg; 2011 Jun; 84(6):923-8. PubMed ID: 21633029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Araj GF; Jaber FA
    J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The trometamol salt of fosfomycin: microbiological evaluation.
    Greenwood D; Coyle S; Andrew J
    Eur Urol; 1987; 13 Suppl 1():69-75. PubMed ID: 3552702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women.
    Minassian MA; Lewis DA; Chattopadhyay D; Bovill B; Duckworth GJ; Williams JD
    Int J Antimicrob Agents; 1998 Apr; 10(1):39-47. PubMed ID: 9624542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
    Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli.
    Ríos E; Del Carmen López Diaz M; Culebras E; Rodríguez-Avial I; Rodríguez-Avial C
    Med Microbiol Immunol; 2022 Dec; 211(5-6):269-272. PubMed ID: 36056943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
    Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
    Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of oral fosfomycin-trometamol in patients with catheter-associated urinary tract infections (CAUTI): new indications for an old antibiotic?
    Cai T; Cocci A; Verze P; Rizzo M; Palmieri A; Liguori G; Trombetta C; Adembri C; Carini M; Bartoletti R; Wagenlehner FM; Bonkat G; Mirone V; Bjerklund Johansen TE; Novelli A
    J Chemother; 2018 Sep; 30(5):290-295. PubMed ID: 30843774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: A systematic review and expert opinion.
    Cai T; Novelli A; Tascini C; Stefani S
    Int J Antimicrob Agents; 2023 Dec; 62(6):106983. PubMed ID: 37748624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High antimicrobial resistance in urinary tract infections in male outpatients in routine laboratory data, Germany, 2015 to 2020.
    Salm J; Salm F; Arendarski P; Kramer TS
    Euro Surveill; 2022 Jul; 27(30):. PubMed ID: 35904060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rationale for choosing an antibiotic for the treatment of cystitis: recommendations of clinical pharmacologists: A review].
    Yakovlev SV; Suvorova MP
    Ter Arkh; 2022 Oct; 94(8):1006-1013. PubMed ID: 36286982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
    Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
    Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Sensitivity to Fosfomycin in Extended-spectrum Betalactamase-producing Escherichia coli].
    Lifonzo-Mucha SJ; E Tamariz-Zamudio P; Champi-Merino RG
    Rev Peru Med Exp Salud Publica; 2018; 35(1):68-71. PubMed ID: 29924280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of the trometamol salt of fosfomycin in an in vitro model of the treatment of bacterial cystitis.
    Greenwood D
    Infection; 1986; 14(4):186-9. PubMed ID: 3531023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.